SRF and melanoma: This way, MRTF depletion or use of SRF/MRTF inhibitors (CCG-1423 and CCG-203971) in melanoma cells abolished melanocytic to mesenchymal transition and PLX4720 co-treatment with CCG-257081 overcame tumour growth in mice [34].